MESO is Mesoblast Limited (Healthcare) — a non-dividend-paying stock. Trading at $17.29. Market cap: $2.14B.
Stock snapshot
| Price | $17.29 |
| Market cap | $2.14B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About MESO
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Related non-dividend companies
Other non-dividend stocks investors research alongside MESO. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is MESO's current stock price?
MESO (Mesoblast Limited) is currently trading at $17.29.
Does MESO pay a dividend?
MESO (Mesoblast Limited) does not currently pay a regular dividend.
Track MESO in DiviDrip
Add MESO to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search MESO and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-02. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.